New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml;  ;  ;   - solution for injection - 600mg/4ml - active: clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml       excipient: benzyl alcohol disodium edetate dihydrate hydrochloric acid sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml - solution for injection - 300 mg/2ml - active: clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml excipient: benzyl alcohol disodium edetate nitrogen sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml - solution for injection - 600 mg/4ml - active: clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml excipient: benzyl alcohol disodium edetate nitrogen sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

Israel - English - Ministry of Health

rafa laboratories ltd - clindamycin as phosphate - solution for injection - clindamycin as phosphate 150 mg/ml - clindamycin - clindamycin - the treatment of infections caused by susceptible anaerobic bacteria.

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 300 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometr

United States - English - NLM (National Library of Medicine)

proficient rx lp - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re‑served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co‑li‑tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endomet

United States - English - NLM (National Library of Medicine)

proficient rx lp - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 300 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re‑served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co‑li‑tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endomet

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the  warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract su